Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
RNA-Seq-based transcriptome analysis of Murine Rechallenged Dry Eye Model
Author Affiliations & Notes
  • Hara Fumihiro
    Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Takenori Inomata
    Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
    Department of Digital Medicine, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Tianxiang Huang
    Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
    Department of Digital Medicine, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Shokirova Hurramhon
    Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Yuichi Okumura
    Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
    Department of Digital Medicine, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Maria Miura
    Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Keiichi Fujimoto
    Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
    Department of Digital Medicine, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Jaemyoung Sung
    Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
    Department of Ophthalmology, Tulane University School of Medicine, Louisiana, United States
  • Gaku Ishida
    Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Shintaro Nakao
    Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Hara Fumihiro None; Takenori Inomata Santen Pharmaceutical Co., Ltd.; Code P: Renatech Co., Ltd., InnoJin Inc., Code C (Consultant/Contractor), InnoJin, Inc.; , Code E (Employment), Novartis Pharma KK, Santen Pharmaceutical Co., Ltd., Lion Corporation, SEED Co., Ltd., Johnson & Johnson, Shin Nippon Biomedical Laboratories, Ltd., IBM Japan, Ltd.;, Code F (Financial Support); Tianxiang Huang Johnson & Johnson., FUKOKU Co., Ltd.;, Code F (Financial Support); Shokirova Hurramhon None; Yuichi Okumura InnoJin, Inc.;, Code E (Employment), Johnson & Johnson., FUKOKU Co., Ltd.;, Code F (Financial Support), InnoJin, Inc., Code P (Patent); Maria Miura None; Keiichi Fujimoto Johnson & Johnson., FUKOKU Co., Ltd.;, Code F (Financial Support); Jaemyoung Sung None; Gaku Ishida None; Shintaro Nakao Kowa Company. Ltd., Mitsubishi Tanabe Pharma Corporation, Alcon Japan, Ltd., Santen Pharmaceutical Co., Ltd., Machida Endoscope Co., Ltd., Wakamoto Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Senju Pharmaceutical Co., Ltd. Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Hoya Corporation, and Novartis Pharma K.K., Code F (Financial Support)
  • Footnotes
    Support  20K09810,20KK0207,23K15941
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 3621. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hara Fumihiro, Takenori Inomata, Tianxiang Huang, Shokirova Hurramhon, Yuichi Okumura, Maria Miura, Keiichi Fujimoto, Jaemyoung Sung, Gaku Ishida, Shintaro Nakao; RNA-Seq-based transcriptome analysis of Murine Rechallenged Dry Eye Model. Invest. Ophthalmol. Vis. Sci. 2024;65(7):3621.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the gene expression changes of rechallenged dry eye disease (DED) in a
murine model.

Methods : Female C57BL/6 mice aged 6-8 weeks were used for this study. Acute DED was induced
for 14 consecutive days in a controlled desiccative environment for our acute DED group.
Rechallenged DED was developed by transferring the aforementioned acute DED to a standard
vivarium for 3 weeks, followed by an additional 14 days in a controlled desiccative environment.
Samples of cornea, conjunctiva, and cervical lymph nodes from each group were collected for
comparative analysis of differentially expressed gene (DEG) analysis and Gene Ontology analysis
by RNA sequencing.

Results : DEG analysis by RNA sequencing identified characteristic DEGs of the rechallenged DED
group when compared to acute DED group: cornea, 360 genes (up-regulated DEG; 201 genes, down-
regulated DEG; 159 genes); conjunctiva, 4,746 genes (up-regulated DEG; 2082 genes, down-
regulated DEG; 2664 genes); cervical lymph nodes, 956 genes (up-regulated DEG; 497 genes,
down-regulated DEG; 459 genes). Gene Ontology analysis identified Go Terms related to
chemokine activity, inflammatory response, positive regulation of angiogenesis, and innate immune
response in the rechallenged DED group compared to the acute DED group.

Conclusions : The results of this study suggest that immune interactions and inflammation-related Go
Terms may be major contributors to DED, particularly in the setting of repetitive exacerbation of
DED. These findings may imply that genes involved in DED pathogenesis may be dynamic and that
chronic DED may carry unique pathologic underpinnings and features when juxtaposed against the
initial acute phase.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×